




DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration  
Rockville, MD 20857

ANDA 78-494




Actavis Elizabeth LLC  
Attention: Janak Jadeja, R.Ph.  
Director, Regulatory Affairs  
200 Elmora Avenue  
Elizabeth, NJ 07207


Dear Sir:

This is in reference to your abbreviated new drug application (ANDA) dated September 15, 2006, submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (the Act), for Propranolol Hydrochloride Extended-release Capsules USP, 60 mg, 80 mg, 120 mg, and 160 mg.

Reference is also made to your amendments dated January 8, January 26, June 19, July 17, July 25, July 26, and August 8, 2007.

We have completed the review of this ANDA and have concluded that adequate information has been presented to demonstrate that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly the ANDA is approved, effective on the date of this letter. The Division of Bioequivalence has determined your Propranolol Hydrochloride Extended-release Capsules USP, 60 mg, 80 mg, 120 mg, and 160 mg, to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug, Inderal LA Long Acting Capsules, 60 mg, 80 mg, 120 mg, and 160 mg, respectively, of Wyeth Pharmaceuticals, Inc. Your dissolution testing should be incorporated into the stability and quality control program using the same "interim" method proposed in your application. The "interim" dissolution specifications are as follows:





The "interim" dissolution test(s) and tolerances should be finalized by submitting dissolution data from the first three production size batches. These data should be submitted as a "Special Supplement - Changes Being Effectuated" if there are no revisions to be made to the "interim" specifications, or if the final specifications are tighter than the "interim" specifications. In all other instances, the information should be submitted in the form of a Prior Approval Supplement.

Under section 506A of the Act, certain changes in the conditions described in this ANDA require an approved supplemental application before the change may be made.

Postmarketing reporting requirements for this ANDA are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

Promotional materials may be submitted to FDA for comment prior to publication or dissemination. Please note that these submissions are voluntary. If you desire comments on proposed launch promotional materials with respect to compliance with applicable regulatory requirements, we recommend you submit, in draft or mock-up form, two copies of both the promotional materials and package insert directly to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Division of Drug Marketing, Advertising, and Communications  
5901-B Amundale Road  
Beltsville, MD 20705

We call your attention to 21 CFR 314.81(b)(3) which requires that all promotional materials be submitted to the Division of Drug Marketing, Advertising, and Communications with a completed Form FDA 2253 at the time of their initial use.

Sincerely yours,

*(See appended electronic signature page)*

Gary Buehler  
Director  
Office of Generic Drugs  
Center for Drug Evaluation and Research

**This is a representation of an electronic record that was signed electronically and  
this page is the manifestation of the electronic signature.**

/s/

-----  
Robert L. West  
8/10/2007 11:02:39 AM  
for Gary Buehler